Skip to main content
Journal cover image

Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.

Publication ,  Journal Article
Xiao, DY; Luo, S; O'Brian, K; Ganti, A; Riedell, P; Sanfilippo, KM; Lynch, RC; Liu, W; Carson, KR
Published in: Am J Hematol
October 2016

While sarcopenia has been associated with decreased overall survival in diffuse large B-cell (DLBCL) patients, the impact of sarcopenia on treatment tolerance has not been well-studied. We evaluated the association of sarcopenia with febrile neutropenia hospitalization, treatment-related mortality, and ability to complete standard number of cycles in a retrospective cohort of United States veterans diagnosed with DLBCL between 1998 and 2008 and treated with cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without rituximab. Baseline body composition parameters were evaluated using computed tomography analysis. In total, 522 patients were included in the study, of whom 245 (47%) had baseline sarcopenia. After controlling for other variables, baseline sarcopenia was independently associated with increased risk of febrile neutropenia hospitalization (adjusted Odds Ratio (aOR) 1.64, 95% confidence interval (CI) 1.01-2.65) and inability to complete standard number of treatment cycles (aOR 1.49, 95% CI 1.02-2.16) compared with no baseline sarcopenia. There was a non-statistically significant trend toward higher treatment-related mortality in sarcopenic patients than non-sarcopenic patients (aOR 1.77, 95% CI 0.92-3.41). Sarcopenia is associated with increased risk of treatment intolerance and may be useful in guiding treatment planning and supportive care measures. Am. J. Hematol. 91:1002-1007, 2016. © 2016 Wiley Periodicals, Inc.

Duke Scholars

Published In

Am J Hematol

DOI

EISSN

1096-8652

Publication Date

October 2016

Volume

91

Issue

10

Start / End Page

1002 / 1007

Location

United States

Related Subject Headings

  • Vincristine
  • Veterans
  • United States
  • Treatment Outcome
  • Sarcopenia
  • Prednisone
  • Neutropenia
  • Middle Aged
  • Maximum Tolerated Dose
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Xiao, D. Y., Luo, S., O’Brian, K., Ganti, A., Riedell, P., Sanfilippo, K. M., … Carson, K. R. (2016). Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. Am J Hematol, 91(10), 1002–1007. https://doi.org/10.1002/ajh.24465
Xiao, Daphne Y., Suhong Luo, Katiuscia O’Brian, Arun Ganti, Peter Riedell, Kristen M. Sanfilippo, Ryan C. Lynch, Weijian Liu, and Kenneth R. Carson. “Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.Am J Hematol 91, no. 10 (October 2016): 1002–7. https://doi.org/10.1002/ajh.24465.
Xiao DY, Luo S, O’Brian K, Ganti A, Riedell P, Sanfilippo KM, et al. Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. Am J Hematol. 2016 Oct;91(10):1002–7.
Xiao, Daphne Y., et al. “Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.Am J Hematol, vol. 91, no. 10, Oct. 2016, pp. 1002–07. Pubmed, doi:10.1002/ajh.24465.
Xiao DY, Luo S, O’Brian K, Ganti A, Riedell P, Sanfilippo KM, Lynch RC, Liu W, Carson KR. Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. Am J Hematol. 2016 Oct;91(10):1002–1007.
Journal cover image

Published In

Am J Hematol

DOI

EISSN

1096-8652

Publication Date

October 2016

Volume

91

Issue

10

Start / End Page

1002 / 1007

Location

United States

Related Subject Headings

  • Vincristine
  • Veterans
  • United States
  • Treatment Outcome
  • Sarcopenia
  • Prednisone
  • Neutropenia
  • Middle Aged
  • Maximum Tolerated Dose
  • Male